A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase III trial adopts a randomized, open label, positive drug control, and multicenter trial design. Subjects who meet the criteria are randomly divided into 1:1 groups and receive treatment with TQB2102 injection or docetaxel combined with trastuzumab and pertuzumab, respectively.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chęć udziału w badaniu i dobre stosowanie się do zaleceń.
- •Wiek od 18 do 75 lat.
- •Rak piersi HER2-dodatni, który powrócił lub rozsiał się, potwierdzony badaniami.
- •Nie stosowano leczenia przeciwnowotworowego od momentu nawrotu/rozsiewu (możliwe dotychczasowe leczenie hormonalne).
- •Przynajmniej jedna widoczna zmiana chorobowa.
- •Dobra ogólna kondycja narządów wewnętrznych.
✗ Disqualifies
- •Zaawansowane przerzuty do mózgu lub rdzenia kręgowego.
- •Inne nowotwory w ciągu ostatnich 5 lat.
- •Ciężkie, nieustępujące powikłania po wcześniejszym leczeniu.
- •Zabiegi operacyjne lub urazy w ciągu ostatnich 4 tygodni.
- •Problemy z krzepliwością krwi.
- •Zakrzepica żył głębokich lub zator tętniczy w ciągu ostatnich 6 miesięcy.
- •Niekontrolowane infekcje.
- •Problemy z płucami.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- June 25, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (25)
Anhui Provincial Cancer Hospital
Hefei, China
Anhui Provincial Hospital
Hefei, China
Beijing Tiantan Hospital,Capital Medical University
Beijing, China
Gansu Provincial Cancer Hospital
Lanzhou, China
Gansu Provincial Cancer Hospital
Lanzhou, China
Shantou Central Hospital
Shantou, China
Affiliated Cancer Hospital of Harbin Medical University
Harbin, China
Huaihe Hospital of Henan University
Kaifeng, China
Puyang Oilfield General Hospital
Puyang, China
The Third People's Hospital of Zhengzhou
Zhengzhou, China
Zhongnan Hospital of Wuhan University
Wuhan, China
Hunan Cancer Hospital
Changsha, China
Jiangsu Provincial People's Hospital
Nanjing, China
The first hospital of Jilin University
Changchun, China
Affiliated Zhongshan Hospital Of Dalian University
Dalian, China
Affiliated Zhongshan Hospital Of Dalian University
Dalian, China
Liaoning Provincial Cancer Hospital
Shenyang, China
The First Affiliated Hospital of Xi'An Jiaoting Yniversity
Xi'an, China
Cancer Hospital of Shandong First Medical University
Jinan, China
Fudan University shanghai cancer center
Shanghai, China
Shanxi Cancer Hospital
Taiyuan, China
Yuncheng Central Hospital, Shanxi Province
Yuncheng, China
Tianjin Cancer Hospital Airport Hospital
Tianjin, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
The Affiliated Tumor Hospital of Xinjiang Medical University
Ürümqi, China
Trial contact
Zhimin Shao, Doctor
Yongmei Yin, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.